Molecular Biometrics Closes $12.5M Financing Round

Jan 13, 2010

NEW YORK (GenomeWeb News) – Metabolomics company Molecular Biometrics said yesterday that it has completed a $12.5 million Series B financing.

New investor Atlas Ventures led the financing round with participation from existing investors Safeguard Scientifics and Oxford Bioscience Partners.

Based in Norwood, Mass., Molecular Biometrics will use the cash to accelerate the global launch of its lead product, ViaMetrics-E, a rapid, non-invasive procedure designed to enhance in vitro fertilization outcomes by using cellular metabolomic signatures.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Links Between Them

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

Retaliation Claim

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

Good Samples Under the Glass

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

This Week in PNAS

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.

Featured White Papers

A Mammalian System for Antibody/Protein Library Screening

iPSC & CRISPR/Cas9 Technologies Enable Precise & Controlled Physiologically Relevant Disease Modeling for Basic & Applied Research

Contract Manufacturing in Biotech: Turning Your Supply Chain Into a Competitive Differentiator

Tissue Section Imaging

Nov

27

Featured Webinar

Defining a Multi-Omics Target Discovery Framework for High-Risk Cancers

While next-generation sequencing (NGS) has driven recent advances in precision oncology research, it often falls short when identifying the molecular mechanisms underlying many malignancies. As a result, alternative NGS-based approaches are needed to identify oncogenic drivers and potential drug targets.

Dec

06

Featured Webinar

Mapping The Disease-Variant Landscape To Accelerate Precision Drug Development

Rhythm Pharmaceuticals and Genomenon will discuss their efforts to assemble a database of mutations associated with rare genetic disorders of obesity, and how this was optimized to facilitate a deep understanding of the variant landscape of melanocortin-4 receptor (MC4R)-pathway genes. This database may help identify MC4R-pathway deficient individuals who might benefit from future precision therapies.

Main menu